Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo

In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment

Read more at globenewswire.com